The innovator actually has a lot of brush to clear away in terms of regulation, reimbursement, physician habits and more. The imitatorn can sometimes do betterd and even some of the sort of more distant follow on. Now, if you're looking at some of the stuff going on in crisper, you still have to, i mean, honestly, just have to focus on the science at this point.
Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the possibilities for CRISPR, from sickle cell cures to drought-resistant crops - How investors can approach investing in gene therapies - Biotech metrics to watch.
Companies mentioned: BLUE, CRSP, GILD, EDIT, VRTX, NTLA
Host: Ricky Mulvey Guest: Karl Theil Engineers: Tim Sparks, Dan Boyd
Learn more about your ad choices. Visit megaphone.fm/adchoices